The stock of Sana Biotechnology Inc (SANA) has seen a -5.05% decrease in the past week, with a -24.83% drop in the past month, and a 35.30% flourish in the past quarter. The volatility ratio for the week is 13.31%, and the volatility levels for the past 30 days are at 10.14% for SANA. The simple moving average for the past 20 days is -14.76% for SANA’s stock, with a -44.87% simple moving average for the past 200 days.
Is It Worth Investing in Sana Biotechnology Inc (NASDAQ: SANA) Right Now?
The stock has a 36-month beta value of 1.63. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for SANA is 125.16M, and at present, short sellers hold a 33.56% of that float. On March 25, 2025, the average trading volume of SANA was 7.59M shares.
SANA) stock’s latest price update
The stock of Sana Biotechnology Inc (NASDAQ: SANA) has decreased by -10.54 when compared to last closing price of 2.42.Despite this, the company has seen a loss of -5.05% in its stock price over the last five trading days. prnewswire.com reported 2025-03-25 that NEW YORK, March 25, 2025 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Citizens JMP repeating the rating for SANA by listing it as a “Mkt Outperform.” The predicted price for SANA in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 18, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see SANA reach a price target of $7. The rating they have provided for SANA stocks is “Buy” according to the report published on March 14th, 2025.
SANA Trading at -25.83% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.38% of loss for the given period.
Volatility was left at 10.14%, however, over the last 30 days, the volatility rate increased by 13.31%, as shares sank -15.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.03% lower at present.
During the last 5 trading sessions, SANA fell by -3.73%, which changed the moving average for the period of 200-days by -71.97% in comparison to the 20-day moving average, which settled at $2.54. In addition, Sana Biotechnology Inc saw 32.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from CHRISTIAN HORDO & KATHARINE HO, who proposed sale 75,000 shares at the price of $3.16 back on Feb 18 ’25. After this action, CHRISTIAN HORDO & KATHARINE HO now owns shares of Sana Biotechnology Inc, valued at $237,000 using the latest closing price.
CHRISTIAN HORDO & KATHARINE HO, the Officer of Sana Biotechnology Inc, proposed sale 75,000 shares at $3.86 during a trade that took place back on Jan 16 ’25, which means that CHRISTIAN HORDO & KATHARINE HO is holding shares at $289,500 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.59. Equity return is now at value -99.17, with -50.03 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.37.
Currently, EBITDA for the company is -272.72 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.
Conclusion
To sum up, Sana Biotechnology Inc (SANA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
